Back

Exploration of cyclophilin A antibody anti-eCypA as a new approach in the treatment of marfan syndrome

31 August 2025 (11:15 - 12:00)
Organised by: Logo
Congress Presentation Part of: Hereditary connective tissue disorders Treatment ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Ms Henrike Witthaus

Kiel (Germany)

6 More presentations in this session

Presentation thumbnail
Vascular involvement in loyes-dietz syndrome: distribution and prevalence of aneurysms and dissections across different vascular territories
Doctor L. Dreher (Scottsdale, US)
Abstract Slides Video
Presentation thumbnail
Health-related quality of life is impaired in marfan syndrome and is strongly associated with lower exercise capacity
Doctor G. Teixido Tura (Barcelona, ES)
Abstract Slides Video
Presentation thumbnail
Evaluation of the impact of a cardiac rehabilitation program on exercise capacity and cardiocirculatory parameters in patients with Marfan syndrome
Doctor C. Badia Molins (Badalona, ES)
Abstract Slides Video
Presentation thumbnail
Evaluation of exercise capacity and cardiovascular parameters through cardiopulmonary exercise testing in patients with Marfan syndrome.
Doctor A. Hernandez-Pineda (Barcelona, ES)
Abstract Slides Video
Presentation thumbnail
Phenotypical variability beyond the genotype/phenotype correlation in patients with FBN1 pathogenic variant
Doctor G. Jondeau (Paris, FR)
Abstract Slides Video

Access the full session

Session thumbnail
Hereditary connective tissue disorders

The Event

Event poster

ESC Congress 2025

31 August 2025 11:15 CET
You may be interested in
thumbnail
Congress Presentation
Oral low-dose rapamycin treatment prevents aortic aneurysms in marfan mice
thumbnail
Congress Presentation
Targeting mitochondrial stress with SS31 reduces ascending aortic dilation and improves cardiac performance in a preclinical model of Marfan disease.
thumbnail
Congress Presentation
Unraveling Marfan hearts: ultrastructural evidence for myocardial remodeling and cardiomyopathy

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources